SC
SKYE icon

Steven Cohen’s Skye Bioscience SKYE Stock Holding History

Steven Cohen’s Portfolio SKYE Stock Details SKYE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-416,424
Closed -$1.63M – 2533
2024
Q3 		$1.63M Sell
416,424
-143,576
-26% -$805K ﹤0.01% 1265
2024
Q2 		$4.49M Buy
+560,000
New +$6.64M 0.01% 862

Other funds holding SKYE

5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
Altium Capital Management New York $47.5M AUM 115.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return

Steven Cohen's SKYE Position: Q4 2024 in Review

Steven Cohen sold out of Skye Bioscience (SKYE) in Q4 2024, closing a stake of 416,424 shares — an estimated $1.63M sold.

Steven Cohen first reported a position in SKYE in Q2 2024 and held it in 2 quarters. The position peaked at $4.49M in Q2 2024. 73 funds tracked by Wall St. Rank hold SKYE as of Q4 2024.

  • Steven Cohen reported no remaining Skye Bioscience position as of Q4 2024 after selling out during the quarter.
  • Steven Cohen sold 416,424 Skye Bioscience shares in Q4 2024, an estimated $1.63M.
  • Steven Cohen first reported a position in Skye Bioscience in Q2 2024 and held it in 2 quarters.
  • Steven Cohen's Skye Bioscience position peaked at $4.49M in Q2 2024.
  • 73 funds tracked by Wall St. Rank held Skye Bioscience as of Q4 2024.

Based on Point72 Asset Management's 13F filing for Q4 2024, filed 14 Feb 2025.